Clinical Trial Update: A Multicenter Trial of Sprifermin (AS902330 [Recombinant Human Fibroblast Growth Factor-18]) or Placebo After Microfracture Surgery for Cartilage Injury of the Knee [Phase 2]

View source ↗

Summary

A multicenter Phase 2 trial evaluating Sprifermin (recombinant human fibroblast growth factor-18) versus placebo after microfracture surgery for knee cartilage …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cartilage Injury of the Knee

Drugs mentioned

• Sprifermin (sprifermin)

Snippet

Sponsor: EMD Serono | Conditions: Cartilage Injury of Knee | Phase 2 | Status: TERMINATED | Results posted: 2015-08-31